Business
University of Manchester collaboration discovery
University of Manchester collaboration discovery.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 1273C Evgen Pharma PLC 06 February 2020 \n\nEvgen Pharma plc\n (\"Evgen Pharma\" or the \"Company\")\n \nUniversity of Manchester collaboration discovery\n \nGene signature identified which may determine response to SFX-01 in ER+ breast cancer treatment\nEvgen closer to predicting which patients are most likely to benefit from breast cancer drug\n \nEvgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces that its long-standing collaboration with the University of Manchester has led to the discovery of a gene signature that may predict patient response to SFX-01 in advanced oestrogen receptor positive (''ER+'') breast cancer.\n \nEvgen and the University of Manchester have previously shown that SFX-01 inhibits activity of STAT3; a transcription factor known to play a role in therapy resistance, and in the spread of the cancer around the body. In this latest study, in hormone therapy resistant patient tumours, SFX-01 was shown to inhibit expression of key STAT3-regulated genes. This discovery yields further insight into the mechanism of action of SFX-01 and moves the Company closer to determining which patients are most likely to respond favourably to treatment.\n \nAll the preclinical data accrued over the last eight years of this research collaboration is to be published later this year and the manuscript is now in open access and can be viewed at:\n \nhttps://biorxiv.org/cgi/content/short/2020.02.03.932194v1\n \nThis follows a short preview of some of the data that was presented by poster at last week's UK Interdisciplinary Breast Cancer Symposium in Birmingham, UK. \n \nEvgen Pharma has previously announced positive results from the STEM trial of SFX-01 in metastatic breast cancer. Patients who responded favourably to SFX-01 were able to access it post trial and we can now report that one patient had their progressive disease halted for a total of 597 days; an impressive duration in a very difficult to treat and terminally ill patient population.\n \nSteve Franklin, CEO of Evgen Pharma, said: \"This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive development...